Introduction
Tuberculosis is a leading cause of death, especially in low and middle income countries (1) . China is one of the 22 high TB burden countries. The latest estimates included in the global TB report of 2014 that there were 9.0 million new TB cases in 2013 and 1.5 million TB deaths, among them China accounted for 11% new tuberculosis (2) . Nevertheless, most deaths from TB are preventable by early diagnosis and treatment. Totally 37 million lives were saved between 2000 and 2013 through effective diagnosis and treatment (2) . However recent studies showed extensive delay in TB diagnosis and treatment were severe (3) . Hence, the crucial point to eradicate the disease is improving the diagnosis of tuberculosis. In high prevalence of TB areas, the sputum smear microscopy test, with a sensitivity of 50%-70%, is available and affordable (4) . Although smear-negative cases are less infectious than smear-positive cases, at least 17% of TB cases are affected by smear-negative cases (5) . The Mycobacterium culture is the golden standard for TB diagnosis, but the detection results cost a long time and have a low positive rate, the sensitivity of 43%-83% (6) . PCR test has found an increasingly wide utilization in TB diagnosis, but in developing areas its utilization remains limited because of the high cost of detection and the deficiency of special equipment and professional staffs (7, 8) . Therefore, the cheap, accurate and rapid diagnostic tests for TB are much-needed (9) . In recent years, serum tumor markers were an effective and non-invasive diagnostic tool (10) , and became a common clinical method for screening tumor (11) . Interestingly, a study in 1995 reported that CA125 was increased in PTB (12) , since then several studies reported that the serum levels of CA125, CA199, CEA in PTB were higher than those in normal population (13) (14) (15) (16) . The results provided a clue that tumor markers had potential clinical value for the diagnosis of PTB possibly. However, the study on the predictive power of tumor markers and which tumor marker has higher sensitivity and specificity in diagnosis of PTB are uncleared. In this study, we aimed to evaluate the sensitivity, specificity and cut-off of serum tumor markers to PTB diagnosis by ROC, and expected to evaluate the correlations between serum tumor markers and clinically relevant parameters of PTB.
Materials and Methods

Study subjects
This study was designed as a case-control study with 565 subjects who visited the Yijishan Hospital from Jun to Dec in 2014. Case group was selected from subjects with PTB diagnosed by physicians according to reference (17) . Cases were excluded if there was a change in diagnosis during the treatment period, and the smokers were not enrolled in this study. Control group was selected from individuals who underwent physical examination in Center of Health Examination of Yijishan Hospital during the same period. If the subjects with systemic infections, history of pulmonary tuberculosis, closely contact with PTB patients, tumor, neoplastic diseases and gynecological disorders were excluded from control group. We also excluded the subjects who were in inflammatory conditions (confirmed by standard diagnostic criteria) with clinical features that could overlap the TB. For example, subjects with differential diagnosis of PTB, and other severe respiratory infections representing patients who had non-tuberculous destructive pulmonary pathology. The case group was matched age and sex with control group. The distribution of PTB cases and controls was not intended to reflect a particular population or epidemiological setting, but to encompass a broad range of symptomatically overlapping clinical presentations. The information including demographic characteristics was extracted from the electronic medical record. The protocol of this study was approved by Medical Ethics Committee of Wannan Medical College, all participants had been informed about the study and gave their consent.
Serum tumor marker detection
All participants were characterized by sputum smear microscopy and culture including subsequent antigen or molecular confirmation of M. Tuberculosis. Serum samples were collected within 2 days of the first presentation and before initiation of treatment for PTB patients. Three milliliter venous blood was collected from the patients fasted for 12 h and then centrifuged and stored at −70 °C until assayed. Serum CEA, CA125 and CA199 were detected by Roche electrochemiluminescence instrument at Department of Nuclear Medicine of Yijishan Hospital. All detection reagents were the corresponding bundled reagents, and its operation was in strict accordance with the manual. The normal reference values were as follows: CEA≤5ng/ml, CAl25≤35 U/ml, and CAl99≤ 37 U/ml.
Statistical analysis
Before analysis, means (SD) or median (25th percentile, 75th percentile) was calculated for continuous variables and proportions for categorical variables. Chi-square test was conducted to compare the differences of demographic characteristics between case and control groups. And the mean concentrations of CA125, CA199 and CEA between initial treatment and retreatment, case group and control group were tested by Kruskal-Wallis method of nonparametric test. In our study, the concentrations data of CA125, CA199 and CEA like other references are not normal distribution, and then we selected the non-parametric tests. Furthermore, the Mann-Whitney U test was applied to determine the abnormal rates of three tumor markers between case group and control group. Followed was identified the related serum tumor markers to PTB by logistic regression analysis. Then the ROC curve analysis was conducted to assess the difference between areas under the curve (AUC) which belonged to respective tumor marker and to evaluate the diagnostic sensitivity and specificity at the optimal cut-off. P<0.05 was considered to indicate a statistically significant difference. Data management and all analyses were performed using R software program, version 3.0.0 (http://www.R-project.org).
Results
Demographic characteristics
The case group was completed on 113 cases, including 58 PTB initial treatment patients (37 men, 21 There were no significant differences of age, sex and smoking between case and control group. In terms of drink and marital status, there were significantly different between two groups ( Table 1 ).
The analysis of concentration levels and abnormal rates of three tumor markers between case and control groups
The concentration of serum CA125, CA199 and CEA in case group were found significantly higher than those in control group (P<0.001) ( Table  2) . We also accessed the abnormal rates of three tumor markers between two group, the abnormal rates of CA125 (Case group: 48.67% vs Control group: 0.22%) and CEA (Case group: 7.08% vs Control group: 0.88% ) in case group were significantly higher than in control group (P<0.001). The abnormal rate of CA199 was no significant different between two groups (Table 3) . 
The analysis of concentration levels of three tumor markers between initial treatment and retreatment group
To understand whether the retreatment of PTB effect the three tumor markers, we test the levels of serum CA125, CA199 and CEA, there were no significant differences between initial treatment group and retreatment group.
Evaluation the association of three tumor markers with PTB
The logistic regression analysis was performed to evaluate the association of three tumor markers with PTB, PTB (case group=1, control group=0) was selected as dependent variable, and CA125, CA199 and CEA were selected as independent variables. The results showed that CA125 was significantly related to PTB (OR = 1.133, P<0.001) ( Table 4 ). The analysis of predictive value of three tumor markers by ROC
The ROC analysis revealed that for CA125, the AUC whose 95% confidence interval ranges from 0.951 to 0.981 was 0.966, and the cut-off value was 10.30, with the sensitivity, specificity 0.956 and 0.850, respectively.
Discussion
In this study we investigated the diagnostic value of three common clinical serum tumor markers, the CA125, CA199 and CEA in case group were found significantly higher than those in control group, but only CA125 was the positive association factor with PTB, the value of predictive power (AUC) was 0.966, the cut-off, sensitivity and specificity of CA125 were 10.30 U/ml, 0.956 and 0.850, respectively.
CA125 was identified by molecular cloning (18) and presents in the tracheal, bronchial, bronchiolar, terminal bronchiolar epithelium (19) , as a cell surface glycoprotein involved in promoting ovarian cancer cell growth, and it was considered as a specific biological marker for ovarian cancer. However, our study suggested that CA125 was significantly higher PTB patients both in treatment and retreatment, and had higher sensitivity and specificity compare to another Study (15) . The possible reason was that severe PTB was associated with more bronchial epithelial cells destruction, which induced the elevated CA125 level in PTB patients (16) . A study in Germany explained that it was the inflammatory mesothelial cell proliferation, which induced the secretion of CA125 in patients with TB (20) . CA199 is another common clinical tumor marker in diagnosis pancreatic cancer (21) and gastric cancer (22) . We selected CA199 and tested the diag-nosis of predictive value to PTB, since there several case reports showed that CA199 was increased in a PTB patient (23) and in an endobronchial TB patient (24) . However, this study found that CA199 had no significant to PTB in multivariables logistic aggression analysis. Canturk Tasci, et al. also reported that there were no statistically significant in CA199 values of PTB group before treatment when compared with that of the healthy control group, and the difference found in CA199 levels before and after treatment in patients with PTB was not statistically significant (P<0.08) (25) . The reason has been unknown, whatever the results of case report may influenced by some casual factors.
A report in 1993 demonstrated that elevated serum CEA was found in 16.9% of patients with active pulmonary tuberculosis (26) . Especially in female, a report showed that among 6 to 7 female patients with miliary tuberculosis, CEA had elevated (27) . These finds were similar to our results, but in our study, CEA in male (1.35) was significantly higher than that in female (0.89), and the AUC of CEA was only 0.710. Thus diagnosing PTB with CEA is not a good method. Differentiating pulmonary tumor from PTB is difficult, in our study there 48.67% PTB case were abnormal according to CA125 normal reference, interestingly, the cut-off in ROC curve of CA125 was 10.30, and it was significantly lower than its normal references of tumor ≤ 35U/ml. In other words, it may be a potential bio-marker which can differentiate the pulmonary tumor from PTB. The present study has several limitations. Firstly, the patients in case group of this study were recruited only with PTB, thus the results may not be applicable in other type TB. Secondly, both case and control groups, we excluded patients according to imaging findings and clinical experiences instead of tissue biopsy, it was inevitable that the PTB and tumor patients incubation period were enrolled this study. Thirdly, all patients in our study were characterized by sputum smear microscopy and culture including subsequent antigen or molecular confirmation of Mycobacterium TB to determine the reference standard, so these results may be not applicable in smear-negative PTB. The mechanism of the association of the serum tumor markers with PTB remains to be further explored.
Conclusions
Serum CA125 has good diagnostic performances for PTB, this diagnostic accuracy would surpass that of other available immediate diagnostic options, and could yield a result much more rapidly than cultures.
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